A new hope for precision medicine.

Abstract	The SS1P immunotoxin is combined with immunomodulatory therapy in order to improve its efficacy in human mesothelioma (Hassan et al., this issue).
Authors	Ravi Salgia, Martin Sattler
Journal	Science translational medicine (Sci Transl Med) Vol. 5 Issue 208 Pg. 208fs38 (Oct 23 2013) ISSN: 1946-6242 [Electronic] United States
PMID	24154598 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S., Comment)
Chemical References	Antibodies, Monoclonal GPI-Linked Proteins SS1(dsFv)PE38 Mesothelin
Topics	Antibodies, Monoclonal (therapeutic use) Female GPI-Linked Proteins (immunology) Humans Immunosuppression Therapy Male Mesothelin Mesothelioma (immunology, therapy) Peritoneal Neoplasms (immunology, therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!